BioAtla Reports Lower Q3 R&D Expenses and Confirms Partnership Plans by Year End

BioAtla Inc. announced its financial results for the third quarter ended September 30, 2025, and provided updates on its clinical programs. The company reported research and development (R&D) expenses of $9.5 million for the quarter, a decrease from $16.4 million in the same period in 2024. The $6.9 million reduction was attributed to lower program development costs, reduced headcount-related expenses following a workforce reduction in March 2025, and lower non-cash stock-based compensation. BioAtla stated that R&D expenses are expected to continue declining through the remainder of 2025 as resources are concentrated on prioritized programs. The company also highlighted progress in its clinical pipeline, including FDA alignment on the Phase 3 Oz-V trial design for the treatment of second-line and later (2L+) oropharyngeal squamous cell carcinoma (OPSCC), with dual primary endpoints and the potential for accelerated approval. BioAtla is in advanced stages of finalizing a strategic partnership transaction, targeted for completion by year end. Updates were provided on the ongoing BA3182 trial in advanced adenocarcinomas, with a readout expected in the first half of 2026, and the achievement of a milestone in the CAB-Nectin4-TCE program under a license agreement with Context Therapeutics. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-280141), on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here